Effects of 17α-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: Reduced biliary excretion and hepatic metabolism of doxorubicin

Xenobiotica

Volumn 43, Issue 10, 2013, Pages 901-907

  Choi, Young Hee ^a   Lee, Yu Kyung ^a   Lee, Myung Gull ^b  

^a Dongguk University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

17 Ethynylestradiol; Cholestasis; Cytochrome P450; Doxorubicin; Hepatic metabolism; Hepatobiliary excretion; Multidrug resistance associated protein 2; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A; DOXORUBICIN; ETHINYLESTRADIOL; MULTIDRUG RESISTANCE PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE FLOW; BILIARY EXCRETION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; EQUILIBRIUM DIALYSIS; FEMALE; FLOW RATE; INTRAHEPATIC CHOLESTASIS; LIVER METABOLISM; LIVER MICROSOME; LOADING DRUG DOSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BILE; CHOLESTASIS; CYTOCHROME P-450 CYP3A; DOXORUBICIN; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; LIVER; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84884239991     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.783250     Document Type: Article

References (45)

1. Ballet F, Vrignaud P, Robert J, et al. (1987). Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol 19:240-5 (Pubitemid 17121277)
2. Borst P, Elferink RO. (2002). Mammalian ABC transporters in health and disease. Ann Rev Biochem 71:537-92 (Pubitemid 34800230)
3. Chan LM, Lowes S, Hirst BH. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51 (Pubitemid 38050202)
4. Chiou WL. (1978) Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve J Pharmacokinet Biopharm 6:539-46
5. Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543-52 (Pubitemid 44726394)
6. Choi YH, Lee U, Lee BK, Lee MG. (2010). Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol 161:815-29
7. Choi JS, Piao YJ, Kang KW. (2011). Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607-13
8. Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, et al. (2001). Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 34:329-39 (Pubitemid 32702346)
9. Cui Y, Konig J, Buchholz JK, et al. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-37 (Pubitemid 29214613)
10. Czeczuga-Semeniuk E, Solczynski S, Dabrowska M, et al. (2004). The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells. Folia Histochem Cytobiol 42: 221-7 (Pubitemid 39481029)
11. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-5 (Pubitemid 23211439)
12. Denk GU, Soroka CJ, Takeyama Y, et al. (2004). Multidrug resistanceassociated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40:585-91 (Pubitemid 38367779)
13. Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61-90
14. Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-717
15. Eloranta ML, Heinonen S, Mononen T, Saarikoski S. (2001). Risk of obstetric cholestasis in sisters of index patients. Clin Genet 60:42-5 (Pubitemid 32677781)
16. Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York: Marcel Dekker
17. Hidemura K, Zhao YL, Ito K, et al. (2003). Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob Agents Chemother 47:1636-42 (Pubitemid 36548548)
18. Jin HE, Hong SS, Choi MK, et al. (2009). Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol- induced cholestasis. Pharm Res 26:549-59
19. Key TJ. (1995). Hormones and cancer in humans. Mutat Res 333:59-67 (Pubitemid 26024119)
20. Lee HJ, Lee MG. (1999). Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res Commun Mol Pathol Pharmacol 105:87-96 (Pubitemid 30395499)
21. Lin HL, Kent UM, Hollenberg PF. (2002). Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 301:160-7 (Pubitemid 34250292)
22. Micheline D, Emmanuel J, Serge E. (2002). Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J Pediatr Gastroenterol Nutr 35:185-91
23. Mottino AD, Cao J, Veggi LM, et al. (2002). Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronideinduced cholestasis. Hepatology 35:1409-19 (Pubitemid 34966895)
24. Muhlfeld A, Kubitz R, Dransfeld O, et al. (2003). Taurine supplementation induces multidrug resistance protein 2 and bile salt export pump expression in rats and prevents endotoxin-induced cholestasis. Arch Biochem Biophys 413:32-40 (Pubitemid 36434349)
25. Okabe M, Unno M, Harigae H, et al. (2005). Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754-62 (Pubitemid 40854224)
26. Pauli-Magnus C, Meier PJ. (2005). Hepatocellular transporters and cholestasis. J Clin Gastroenterol 39:S103-10 (Pubitemid 40397023)
27. Rajkumar L, Guzman RC, Yang J, et al. (2004). Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast Cancer Res 6:R31-7
28. Rocha AB, Lopes RM, Schwartsmann G. (2001). Natural products in anticancer therpay. Curr Opin Pharmacol 1:364-9
29. Rodriguez-Garay EA. (2003). Cholestasis: human disease and experimental animal models. Ann Hepatol 2:150-8
30. Ruiz ML, Villanueva SSM, Luquita MG, et al. (2007). Beneficial effect of spironolatone administration on ethylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistanceassociated protein 2. Drug Metab Dispos 35:2060-6 (Pubitemid 350005196)
31. Savander M, Ropponen A, Avela K, et al. (2003). Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 52:1025-9 (Pubitemid 36765296)
32. Scheffer GL, Kool M, Heijn M, et al. (2000). Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269-77
33. Schwarz EB, Hess R, Trussell J. (2009). Contraception for cancer survivors. J Gen intern Med 24:401-6
34. Sivaraman L, Stephens LC, Markaverich BM, et al. (1998). Hormoneinduced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis 19:1573-81 (Pubitemid 28441859)
35. Smylie MG, Wong R, Mihalcioiu C, et al. (2007). A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 25:155-9 (Pubitemid 46020874)
36. Soucek P, Gut I. (1992). Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22: 83-103
37. Speeg KV, Maldonado AL. (1994). Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 34: 133-6 (Pubitemid 24157977)
38. Stephens RH, O'Neill CA, Warhurst A, et al. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-91 (Pubitemid 32112489)
39. Suzuki T, Zhao YL, Nadai M, et al. (2006). Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 79:455-61 (Pubitemid 43870299)
40. Trauner M, Arrese M, Soroka CJ, et al. (1997). The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113:255-64 (Pubitemid 27281782)
41. Vlaming ML, Mohrmann K, Wagenaar E, et al. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-27
42. Wilkinson GR, Shand DG. (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-90
43. Yao K, Lee ES, Bentrem DJ, et al. (2000). Antitumor action of physiological estradiol on tamoxifem-simulated breast tumors grown in athymic mice. Clin Cancer Res 6:2028-36 (Pubitemid 30305102)
44. Zawaira A, Matimba A, Masimirembwa C. (2008). Prediction of sites under adaptive evolution in cytochrome P450 sequences and their relationship to substrate recognition sites. Pharmacogenet Genomics 18:467-76 (Pubitemid 351780430)
45. Zelcer N, Saek T, Reid G, et al. (2001). Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400-7.